Antibacterial Drugs Market: Global Industry Size, Growth, Share and Forecast to 2025

Published By: Brisk Insights | Published On: May 15, 2017

Key Findings

Antibacterial drugs are being widely used, with increase in infections caused by the aerobic and anaerobic bacteria, gram positive and negative bacteria. These drugs are obtained from bacteria, molds or synthesized de novo. Rising prevalence of infectious diseases, research and development in infectious diseases, and government and institutional research support are the key drivers of the antibacterial drugs market. Multi-drug resistant species, patent expiration of the drugs and penetration of generic drugs might hamper the growth of antibacterial drugs market. However, with rise in geriatric population, nosocomial infections, research and development for innovative drugs for multi-drug resistant species are some of the major factors driving the antibacterial drugs market.


Market Segment Insights

The global antibacterial drugs market is majorly segmented by drug class type into beta-lactams, aminoglycosides, sulfonamides, tetracyclines, quinolones, phenicols, macrolides and miscellaneous antibacterials. Beta-lactams occupies the largest share market of the global antibacterial drugs market followed by the quinolones. These drug class will decline in future during the forecast period, due to leading brands losing its market exclusivity, surge in number of drug resistant bacterial strains and entry of generics in the market.


Regional Insights

Asia Pacific dominates the antibacterial drugs market in 2016 and is anticipated to be the fastest growing market in the forecast period. Asia Pacific is occupying the largest market share, as it is driven large base population infected by varied bacterial infection such as tuberculosis, pneumonia etc., rising disposable income, improving healthcare structure. Next followed up market is North America and Europe, the regions show slow growth in the forecast period due to generic entry and stringent regulatory policies.


Market Competition Assessment:

Key players in the antibacterial drugs market are Novartis AG, Pfizer Inc., Merck & Co., Johnson & Johnson Limited, Astra Zeneca plc, Abbott Laboratories, Sanofi SA, Eli Lilly and Company, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Bayer AG and others.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Antibacterial Drugs Market Portraiture
2.2 Global Antibacterial Drugs Market, by Drug Class, 2016 ($ Million)
2.3 Relativity Analysis: Global Antibacterial Drugs Market, by Geography, 2016 & 2025 ($ Million)

Chapter 3 Antibacterial Drugs Market: Market Dynamics and Outlook
3.1 Antibacterial Drugs Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Antibacterial Drugs Market, 2016 (Value %)

Chapter 4 Global Antibacterial Drugs Market, by Type of Drug Class, 2015-2025 ($ Million)
4.1 Preface
4.2 Aminoglycosides
4.3 B-Lactams
4.3.1 Penicillins
4.3.2 Carbapenems
4.3.3 Cephalosporins
4.4 Tetracyclines
4.5 Sulfonamides
4.6 Quinolones
4.5 Macrolides
4.6 Phenicols
4.7 Miscellaneous Anti-bacterial Drugs
4.8 Pipeline Analysis
4.8.1 Projected sales of Phase III Drugs estimated till 2025 ($ Million) Solithromycin Actoxumab/bezlotoxumab (MK-3415A) Cadazolid Carbavance (meropenem/RPX7009) Eravacycline Omadacycline (PTK-0796) Others
4.8.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Antibacterial Drugs Market, by Geography, 2015-2025 ($ Million)
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, and Rest of APAC)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)

Chapter 6 Company Profiles
6.1 Pfizer Inc.
6.2 Novartis AG
6.3 Merck & Co.
6.4 Astra Zeneca plc
6.5 Johnson & Johnson Limited
6.6 Abbott Laboratories
6.7 Eli Lilly and Company
6.8 Sanofi SA
6.9 Bristol-Myers Squibb Company
6.10 Bayer AG
6.11 GlaxoSmithKline plc



Choose License

Contact Information

: 24/7 Research Support


: +448081890034 (UK)